Related references
Note: Only part of the references are listed.Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet
Tiziano Barbuil et al.
LEUKEMIA (2018)
Myeloproliferative Neoplasms
Jerry L. Spivak
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients
S. Cerquozzi et al.
BLOOD CANCER JOURNAL (2017)
A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: A propensity-matched study
Tiziano Barbui et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Global Burden of Thrombosis Epidemiologic Aspects
Aaron M. Wendelboe et al.
CIRCULATION RESEARCH (2016)
Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
Alessandro M. Vannucchi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
CANCER-ASSOCIATED THROMBOTIC DISEASE Myeloproliferative neoplasms and thrombosis
Tiziano Barbui et al.
BLOOD (2013)
Cardiovascular Events and Intensity of Treatment in Polycythemia Vera
Roberto Marchioli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies
Peter C. Austin
MULTIVARIATE BEHAVIORAL RESEARCH (2011)
Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: a new effect for an old drug?
N. Maugeri et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2006)
Efficacy and safety of low-dose aspirin in polycythemia vera
R Landolfi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
